Razadyne, the brand name for galantamine, is a cholinesterase inhibitor that may temporarily ease or stabilize memory and thinking symptoms in mild-to-moderate Alzheimer's dementia. It does not cure Alzheimer's or stop brain-cell damage, and suitability depends on the diagnosis, symptom severity, organ function, and risks such as digestive problems or a slowed heart rate.
Razadyne is not a treatment for dementia generally. The current U.S. prescribing information from DailyMed indicates it specifically for mild-to-moderate dementia of the Alzheimer's type.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What benefit can Razadyne provide?
- Who most closely matches the evidence?
- What are the main risks?
- How do dose and organ function affect the decision?
What benefit can Razadyne provide?
galantamine is a symptomatic treatment. It may improve or stabilize memory and thinking for a time, but it does not change the underlying course of Alzheimer's disease. In one 26-week study, 24 mg per day produced a statistically significant 3.9-point advantage over placebo on the ADAS-cog cognitive scale.
However, individual responses varied widely, according to the FDA prescribing information. That result describes a difference between treatment groups, not a guaranteed improvement for every person. A practical treatment goal should therefore name the changes that matter, such as steadier thinking or fewer noticeable cognitive declines.
Who most closely matches the evidence?
The closest documented candidate has probable Alzheimer's disease with mild-to-moderate impairment. Trials reviewed by the FDA enrolled people with MMSE scores from 10 to 24.
A prescribing discussion should address whether: Mild cognitive impairment alone does not qualify under the indication. In two two-year MCI trials, 13 of 1,026 galantamine recipients died, compared with one of 1,022 placebo recipients. DailyMed notes that this finding conflicted with results from other galantamine studies.
- The diagnosis is dementia of the Alzheimer's type.
- The impairment is mild to moderate.
- Kidney and liver function allow treatment.
- Cardiac-conduction risks make galantamine less suitable.
- The patient and caregiver have identified realistic signs of benefit.
What are the main risks?
Common adverse effects include nausea, vomiting, diarrhea, dizziness, headache, and decreased appetite. In pooled trials, nausea affected 20.7% of galantamine-treated patients and 5.5% of placebo recipients, as reported in the DailyMed galantamine label. Galantamine can also slow the heart rate, cause heart block, or lead to fainting.
The label advises clinicians to consider every patient at risk for cardiac-conduction effects. In trials, fainting increased with the dose and reached 2.2% among patients taking 12 mg twice daily. Before treatment begins, patients and caregivers should ask what to do if fainting, significant dizziness, persistent digestive symptoms, or reduced appetite occurs. These effects may influence whether continuing or adjusting treatment is reasonable.
How do dose and organ function affect the decision?
More medicine does not necessarily produce more benefit. The current label says 24 mg per day did not provide statistically greater clinical benefit than 16 mg per day. A 32 mg daily dose added no effectiveness and was less well tolerated. Kidney and liver function can limit treatment options.
Moderate hepatic or renal impairment generally limits the dose to 16 mg per day. Galantamine should not be used with severe hepatic impairment or a creatinine clearance below 9 mL/min, according to the July 2025 DailyMed label. Patients and caregivers should bring the diagnosis, recent kidney and liver information, and any history of fainting or cardiac-conduction problems to the prescribing visit. They should also agree on which cognitive changes will be used to judge whether treatment is helping.
